
|Articles|September 1, 2002
- Pharmaceutical Executive-09-01-2002
Top European Trial Sponsors
A CenterWatch survey of 545 European clinical trial investigators named the best pharma companies to work with in clinical development.
Advertisement
A CenterWatch survey of 545 European clinical trial investigators named the best pharma companies to work with in clinical development. Bayer, Lilly, Pharmacia, and AstraZeneca were listed as the top sponsors for their attentive study monitoring, realistic protocol design, and improved staff training. The survey rated more than 30 European pharma companies.
Articles in this issue
about 24 years ago
Pharmaceutical Innovation Under Attackabout 24 years ago
More Statins = Fewer Heart Attacksabout 24 years ago
When Worlds Collideabout 24 years ago
Novo Nordisk Cancels Clinical Trialsabout 24 years ago
Dutch Government Just Says Noabout 24 years ago
Lilly Marketers Cross the Lineabout 24 years ago
Spending Hits a Wallabout 24 years ago
Strangers in the Shadowsabout 24 years ago
Plants and Patentsabout 24 years ago
Industry Audit & Companies of the YearAdvertisement
Related to this article

FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.

FDA Commissioner’s National Priority Voucher program reportedly in limbo for expedited drug reviews.

Eli Lilly breaks ground on a $3.5 billion manufacturing facility in Pennsylvania to produce next-generation obesity treatments like retatrutide.

Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.

Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth up to $1.5 billion for berobenatide, and Parexel’s Stacy Hurt on how patients’ use of AI is reshaping sponsor communication.

Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.

Pfizer and Blackstone Life Sciences sign a co-funding deal in which Blackstone is set to provide up to $1.5 billion through 2028 to advance berobenatide.
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Breaks Ground on $3.5 billion Pennsylvania Manufacturing Site
2
Pharmaceutical Executive Daily: FDA Shelves CNPV Program
3
FDA Pauses Commissioner’s National Priority Voucher Program: Report
4
When Small Protocol Decisions Become Enrollment or Retention Barriers
5

